SCHEMBL5158136

SCHEMBL5158136

CCOC(=O)c1cc2c(OC)cc3ccccc3c2n1Cc1cccc(Br)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.48
F10 P00742 3/20 0.46
CYP19A1 P11511 3/20 0.46
NOD2 Q9HC29 1/20 0.44
NOD1 Q9Y239 1/20 0.44
PLA2G10 O15496 1/20 0.44
PLA2G1B P04054 1/20 0.44
PLA2G2A P14555 1/20 0.44
PLA2G2E Q9NZK7 1/20 0.44
PLA2G2D Q9UNK4 1/20 0.44
POLB P06746 2/20 0.43
TP53 P04637 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
MAPT P10636 2/20 0.41
ALDH1A1 P00352 1/20 0.41
TSHR P16473 1/20 0.41
ATM Q13315 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
PTGES O14684 1/20 0.40
ALOX5 P09917 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5160134 0.90 KMT2A (0.55) KMT2AF10NOD2NOD1PLA2G10
SCHEMBL14608289 0.89 KMT2A (0.48) KMT2AF10NOD2NOD1PLA2G10
SCHEMBL14608171 0.84 KMT2A (0.46) KMT2AF10NOD2NOD1PLA2G10
SCHEMBL5162898 0.78 PLA2G10 (0.55) KMT2APLA2G10PLA2G1BPLA2G2APLA2G2E
SCHEMBL5160158 0.77 PLA2G10 (0.54) KMT2APLA2G10PLA2G1BPLA2G2APLA2G2E
SCHEMBL5159760 0.77 KMT2A (0.49) KMT2ANOD2NOD1PLA2G1BPLA2G2A
SCHEMBL3296461 0.73 NOD2 (0.59) KMT2AF10NOD2NOD1POLB
SCHEMBL6337277 0.73 KMT2A (0.52) KMT2AF10NOD2NOD1PLA2G2A
SCHEMBL18274120 0.71 CYP19A1 (0.47) F10CYP19A1NOD2NOD1POLB
SCHEMBL27403124 0.71 NOD2 (0.69) KMT2AF10NOD2NOD1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1358156-B1 BENZ(G) INDOLES AND THEIR USE AS SPLA2 INHIBITORS LILLY CO ELI (US) 2007-02-21 EP disclosed
EP-1358156-B1 BENZ(G) INDOLES AND THEIR USE AS SPLA2 INHIBITORS LILLY CO ELI (US) 2007-02-21 EP disclosed
US-6916840-B2 Spla2 inhibitors ELI LILLY AND COMPANY (US) 2005-07-12 US disclosed
US-20040063967-A1 Novel spla2 inhibitors BEIGHT DOUGLAS WADE (US) 2004-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063967-A1 Novel spla2 inhibitors PLA2G12A, SPINT2, PLA2G4A KMT2A 2957/4885F10 1291/4885CYP19A1 3517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.